By Fineline Cube 
Shanghai Lishan Biopharmaceuticals Co., Ltd. announced a licensing agreement with Israel‑based Evogene Ltd. (NASDAQ: EVGN) for LS‑LBP‑002, a live biotherapeutic product designed to enhance immunotherapy response in cancer patients. Lishan assumes global development, manufacturing, and commercialization rights, with Evogene receiving milestone payments and tiered royalties.
Deal Structure & Strategic Terms
| Item | Detail |
|---|---|
| Licensor | Evogene Ltd. (Nasdaq: EVGN) |
| Licensee | Shanghai Lishan Biopharmaceuticals Co., Ltd. |
| Asset | LS‑LBP‑002 (formerly BMC128) |
| Technology | Live biotherapeutic product (4 strains of human gut bacteria) |
| Indication | Enhances immunotherapy response, stimulates anti‑tumor immune activity |
| Rights | Global clinical development, manufacturing, and commercialization (Lishan) |
| Financial Terms | Milestone payments + tiered royalties |
| Clinical Stage | Phase I nearing completion (RCC and NSCLC) |
| Next Steps | Phase II initiation; China and US registration applications |
Drug Profile & Clinical Progress
- Mechanism: Composed of four well‑defined human gut bacterial strains that enhance responses to immunotherapy and stimulate anti‑tumor immune activity
- Clinical Data: Phase I trial in renal cell carcinoma (RCC) and non‑small cell lung cancer (NSCLC) demonstrated excellent safety and tolerability with early signs of efficacy
- Strategic Advantage: Addresses growing need for immunotherapy combination strategies in solid tumors
- Market Position: First live biotherapeutic product targeting cancer immunotherapy enhancement to advance to Phase II
Market Impact & Commercial Outlook
- Immunotherapy Enhancement Market: Global market for cancer immunotherapy adjuncts projected to reach $5 billion : by 2030
- Live Biotherapeutics: Emerging field with limited competition; LS‑LBP‑002’s early data provides first‑mover advantage
- Revenue Potential: Analysts estimate peak sales potential of $300–500 million : globally if approved, based on combination therapy pricing
- Strategic Value: Lishan gains differentiated oncology asset; Evogene monetizes its microbiome platform while retaining royalty upside
- Next Steps: Phase II trials to initiate Q2 2026; concurrent US IND and China NDA filings planned for H2 2026
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for LS‑LBP‑002. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.-Fineline Info & Tech